Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873-Reference-Cited by-同舟云学术

Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873

Published:2024-03-22 Issue:4 Volume:15 Page:546-554
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Kato Darryl¹^ORCID,Choy Regina Wai-Yan¹,Canales Eda¹,Dick Ryan A.²,Lake April D.¹,Shapiro Nathan D.¹,Chin Elbert¹,Li Jiayao¹,Zhang Jennifer R.¹,Wu Qiaoyin¹,Saito Roland D.¹,Metobo Sammy³,Aktoudianakis Evangelos¹,Schroeder Scott D.¹,Yang Zheng-Yu¹,Glatt Dylan M.⁴,Balsitis Scott¹,Gamelin Lindsay¹,Yu Mei¹,Cheng Guofeng⁵,Delaney William E.⁶,Link John O.¹

Affiliation:

1. Gilead Sciences, Foster City, California 94404, United States

2. Maze Therapeutics, South San Francisco, California 94080, United States

3. Circle Pharma, South San Francisco, California 94080, United States

4. 23andMe Therapeutics, South San Francisco, California 94080, United States

5. AusperBio Therapeutics Inc., San Mateo, California 94401, United States

6. Assembly Bio, South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00037

Reference42 articles.

1. Hepatitis B cure: From discovery to regulatory approval

2. World Health Organization. Hepatitis B Fact Sheet 2023. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b (accessed on 4 December 2023).

3. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment

4. The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?

5. Hepatitis B Virus Infection — Natural History and Clinical Consequences